APA (7th ed.) Citation

R, M., MC, A., L, M., E, J., S, H., N, I., . . . MJ, E. (2026). MesenSistem-EB: Systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics. Frontiers in immunology, 17, 1789537. https://doi.org/10.3389/fimmu.2026.1789537

Chicago Style (17th ed.) Citation

R, Maseda, et al. "MesenSistem-EB: Systemic Haploidentical Mesenchymal Stem Cell Therapy in Recessive Dystrophic Epidermolysis Bullosa Associated with Clinical Benefits and Correlated with MCP1 and SCD40L Dynamics." Frontiers in Immunology 17 (2026): 1789537. https://doi.org/10.3389/fimmu.2026.1789537.

MLA (9th ed.) Citation

R, Maseda, et al. "MesenSistem-EB: Systemic Haploidentical Mesenchymal Stem Cell Therapy in Recessive Dystrophic Epidermolysis Bullosa Associated with Clinical Benefits and Correlated with MCP1 and SCD40L Dynamics." Frontiers in Immunology, vol. 17, 2026, p. 1789537, https://doi.org/10.3389/fimmu.2026.1789537.